GlassScriptPhysician profile
Angel Qin
NPI 1508155920
$40,638.67
in general payments reported to CMS, 2019-2025
19 companies · $16K in 2025
The $16K reported for 2025 was more than what 85% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60.00 · 2022: $3,894 · 2023: $323 · 2024: $20K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $32K · Travel and Lodging: $2,401 · Food and Beverage: $1,456 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,000 · Education: $17.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $31,810.75 |
| Travel and Lodging | $2,401.27 |
| Food and Beverage | $1,455.63 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,000.00 |
| Education | $17.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $13,496.61 | 2024-2025 | Rybrevant |
| E.R. Squibb & Sons, L.L.C. | $12,768.06 | 2019-2025 | |
| Amgen INC. | $3,894.00 | 2022 | |
| Regeneron Pharmaceuticals, INC. | $2,675.39 | 2023-2024 | Libtayo |
| Genentech USA, INC. | $2,610.03 | 2024 | Tecentriq, Alecensa |
| Abbvie INC. | $2,609.99 | 2024-2025 | |
| Pfizer INC. | $1,118.00 | 2024 | |
| Daiichi Sankyo INC. | $828.30 | 2025 | Datroway |
| Astrazeneca Pharmaceuticals LP | $400.00 | 2025 | Enhertu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.00 | 2025 | |
| Genentech, INC. | $76.27 | 2025 | Tecentriq |
| Regeneron Healthcare Solutions, INC. | $17.02 | 2024 | Libtayo |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angel Qin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.